An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2014
Price : $35 *
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 10 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Oct 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Oct 2014.
- 11 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov